Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) just unveiled an announcement.
On February 24, 2026, Microbot Medical announced that Tampa General Hospital became the first health system in Florida to adopt the LIBERTY Endovascular Robotic System, shortly after the platform received FDA 510(k) clearance. The academic medical center’s decision underscores growing institutional readiness for robotic assistance in peripheral endovascular procedures and highlights LIBERTY’s appeal in addressing radiation exposure and ergonomic strain for physicians.
The adoption at a nationally ranked, high-volume referral center supports Microbot’s early post-clearance commercial momentum during its limited market release, which began in late 2025. With a full U.S. launch planned around the Society of Interventional Radiology conference in April 2026, the Tampa General win signals potential for broader hospital uptake in a large and expanding endovascular market.
The most recent analyst rating on (MBOT) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution designed to improve precision, efficiency and safety in peripheral endovascular interventions.
Backed by a substantial intellectual property portfolio, Microbot Medical targets the sizable U.S. peripheral endovascular market, estimated at about 2.5 million procedures annually. By positioning LIBERTY as a differentiated, radiation- and ergonomics-conscious tool, the company aims to drive wider adoption of robotics across specialties such as vascular surgery, interventional cardiology, electrophysiology and interventional radiology.
Average Trading Volume: 2,255,712
Technical Sentiment Signal: Sell
Current Market Cap: $141M
For a thorough assessment of MBOT stock, go to TipRanks’ Stock Analysis page.